Novocure and Zai Lab Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China
Final data collection is expected in the first half of 2022 ST. HELIER, Jersey & SHANGHAI--(BUSINESS WIRE)--#GastricCancer--Novocure (NASDAQ: NVCR), a...






